ctDNA androgen-receptor changes mark worse prognosis in advanced prostate cancer

Design

Systematic review and meta-analysis (25 studies)

Population

Men with metastatic castration-resistant prostate cancer on enzalutamide or abiraterone

Primary outcome

Prognostic value of ctDNA androgen-receptor alterations (overall and progression-free survival)

Effect

Overall survival hazard ratio 1.99 (95% CI 1.61-2.46); progression-free 2.37 (1.81-3.10)

A blood test that profiles tumour DNA is attractive in metastatic castration-resistant prostate cancer, where repeated biopsies are impractical. This meta-analysis of 25 studies asked what androgen-receptor (AR) gene alterations in circulating tumour DNA tell us about prognosis in men on enzalutamide or abiraterone.

The presence of AR alterations in ctDNA was associated with substantially worse overall survival (hazard ratio 1.99, 95% CI 1.61 to 2.46) and progression-free survival (hazard ratio 2.37, 95% CI 1.81 to 3.10). The associations held across detection methods and sampling times. In men already exposed to next-generation AR-targeted therapy, the overall-survival association weakened and lost significance, while the progression link persisted.

The practical reading is that ctDNA AR status is a useful prognostic marker, flagging men likely to do worse, but it is not yet a treatment-selection tool. Nothing here shows that AR status should steer the choice between one hormonal agent and another; that needs prospective biomarker-stratified trials.

• Meta-analysis of 25 studies of ctDNA androgen-receptor alterations in metastatic castration-resistant prostate cancer.
• AR alterations were linked to worse overall survival (hazard ratio 1.99) and progression-free survival (hazard ratio 2.37).
• Associations held across detection methods and sampling times.
• In men with prior AR-targeted therapy, the overall-survival link weakened and lost significance.
• Use it as a prognostic marker, not yet to choose between hormonal agents.

Why it matters

It clarifies what a common liquid-biopsy finding does and does not justify, preventing an over-reach from prognosis to treatment selection.

Don't overread it

These are prognostic associations with high heterogeneity and possible publication bias; they do not establish that AR status predicts differential benefit from a specific therapy.

The statistics, in plain English

Hazard ratios around 2 mean roughly double the rate of death or progression, a strong prognostic signal; but prognostic is not predictive, so a worse-prognosis marker does not tell you which drug will help more, and between-study heterogeneity was substantial.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.